Eli Lilly's Rapid Revenue Growth vs. Bristol Myers Squibb's Steady Growth
LLY Lilly(Eli) & Co
$1270.75 -1.01%
View chart & analysis → - 1Eli Lilly reported Q2 Mounjaro global sales of $9.9 billion, a 91% increase year-over-year.
- 2Bristol Myers Squibb's growth portfolio accounted for 58% of total Q2 revenue.
- 3Both companies will announce Q3 results on October 29.
So what's the key point?
Eli Lilly's sales for a specific drug increased significantly to $9.9 billion. The next earnings reports for both companies are expected soon.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.